Next-generation immersive mental health technology leverages virtual reality
Rocket VR Health (RVH), a virtual reality digital therapeutics company addressing mental health treatments, has initiated a randomized control trial with Massachusetts General Hospital (MGH), Harvard Medical School's largest teaching hospital. The 80-patient trial is examining the feasibility and preliminary efficacy of RVH's virtual reality digital therapeutic in improving quality of life, symptom burden, psychological distress and self-efficacy in adult patients with blood cancers admitted for hematopoietic stem cell transplantation (HCT) at MGH. Patients undergoing HCT treatment experience immense physical and psychological symptoms during a prolonged four-week hospitalization and endure significant short-term and long-term distress that affects their quality of life and their physical and psychological well-being.
Interactive therapeutic content, such as high-definition doctor holograms and meditations taking place at nature-based locations, is delivered on standalone Pico Neo 3 headsets that use a Qualcomm XR2 processor for next-generation performance and have over 2.5 hours of battery life. The headsets weigh only 1.3 pounds and have an ergonomic design while leveraging gaze-based controls removing the need for physical controllers.
Reference: Rocket VR Health and Massachusetts General Hospital Announce Initiation of Randomized Control Trial Investigating Efficacy of Virtual Reality Digital Therapeutic. BOSTON, March 7, 2023 /PRNewswire.
Trial Launches to Explore Using Virtual Reality to Treat Shortsightedness in Children
July 27th 2023A new trial will determine the effectiveness of using virtual reality to treat myopia in children. The treatment combines the use of a VR headset with a phone app that is designed to stimulate dopamine releases in the retina.